The FDA warned telehealth companies to stop making false claims when selling compounded GLP-1 drugs and other medicines. The agency said companies cannot claim these drugs are FDA-approved, generic, or the same as name-brand versions—because compounded drugs are not reviewed by the FDA before they're sold.

• •FDA warns telehealth companies against calling compounded GLP-1s FDA-approved or generic versions of brand drugs.
• •Compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before they are sold.
• •FDA has already issued warning letters to telehealth companies; searchable via 'telehealth' in its warning letter database.